Research published in Biology Methods & Protocols indicates that patients may experience modest weight loss while remaining on starting doses of GLP-1 medications for extended periods.

A study published August 31 in Biology Methods & Protocols suggests that individuals may achieve weight loss while maintaining the lowest starting doses of GLP-1 medications, such as Wegovy and Zepbound, for longer durations. Researchers analyzed electronic health records to compare weight loss outcomes and side effects associated with sustained low-dose use of these drugs compared to conventional dose escalation.

Weight Loss and Side Effect Findings

The study tracked 814 individuals on low-dose semaglutide and 1,016 individuals on low-dose tirzepatide over one year. Participants taking sustained low-dose tirzepatide lost approximately 5.5% of their body weight, while those on sustained low-dose semaglutide lost about 2.2%. Researchers noted that while low-dose semaglutide was associated with more modest weight loss than higher doses, it also correlated with lower rates of specific side effects, including constipation, nausea, and low blood pressure.

Clinical Perspectives on Dosing

While the findings suggest that starting doses could potentially serve as a long-term maintenance strategy for some patients, experts emphasize that individual responses vary. Dr. Mir Ali, medical director of the MemorialCare Surgical Weight Loss Center, noted that while some patients achieve satisfactory results on low doses, many will eventually require dose escalation to continue losing weight. The study authors clarified that their research did not establish intentional microdosing, and using these medications outside of approved schedules is not FDA- or manufacturer-approved.